Vaginitis
diseaseOn this page
Also known as inflammation of vaginavagina inflammationvaginal Inflammationvaginitis (disease)
Summary
Vaginitis (MONDO:0002234) is a disease with 1 GWAS associations across 6 studies and 39 clinical trials. Top therapeutic interventions include estradiol, butoconazole nitrate, and clindamycin. A subtype of vaginal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 39
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | vaginitis |
| Mondo ID | MONDO:0002234 |
| MeSH | D014627 |
| DOID | DOID:2170 |
| ICD-11 | 290861382 |
| NCIT | C26911 |
| SNOMED CT | 30800001 |
| UMLS | C0042267 |
| MedGen | 21815 |
| Is cancer (heuristic) | no |
Also known as: inflammation of vagina · vagina inflammation · vaginal Inflammation · vaginal inflammation · vaginitis · vaginitis (disease)
Data availability: 1 GWAS association (6 studies) · 1 HPO phenotype.
Disease family
This is a subtype of vaginal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › vaginal disorder › vaginitis
Related subtypes (5): vaginal discharge, leukoplakia of vagina, vaginal neoplasm, polyp of vagina, vaginismus
Subtypes (3): postmenopausal atrophic vaginitis, vulvovaginitis, infective vaginitis
Genetics & variants
GWAS landscape
1 GWAS associations across 6 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs145556999 | 4e-08 | ATP6AP1L - RPL5P16 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90478687 | Verma A | 2024 | 4,403 | 9,467 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480932 | Verma A | 2024 | 4,403 | 9,467 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90478688 | Verma A | 2024 | 3,343 | 25,415 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651660 | Liu TY | 2025 | 1,941 | 116,027 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90478686 | Verma A | 2024 | 946 | 4,126 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90436491 | Zhou W | 2018 | 428 | 399,757 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs145556999 | 5 | 82623810 | G>A,C,T | intergenic_variant | ATP6AP1L - RPL5P16 | 4e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
3 approved, 5 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Benzydamine | Approved (phase 4) |
| Ibuprofen | Approved (phase 4) |
| Naproxen | Approved (phase 4) |
| Clindamycin Phosphate | Phase 3 (in late-stage trials) |
| Clotrimazole | Phase 3 (in late-stage trials) |
| Fluconazole | Phase 3 (in late-stage trials) |
| Metronidazole | Phase 3 (in late-stage trials) |
| Tinidazole | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 39.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 20 |
| PHASE3 | 6 |
| PHASE4 | 4 |
| PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07492654 | PHASE4 | NOT_YET_RECRUITING | Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream |
| NCT07526948 | PHASE4 | NOT_YET_RECRUITING | Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV |
| NCT02444481 | PHASE4 | COMPLETED | Open Study of the Efficacy of the Local Treatment With Polygynax of Bacterial and/or Mycotic Vaginitis |
| NCT04079218 | PHASE4 | COMPLETED | Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial |
| NCT04574089 | PHASE3 | RECRUITING | Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository |
| NCT00137371 | PHASE3 | COMPLETED | Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis |
| NCT00313131 | PHASE3 | COMPLETED | Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments |
| NCT00616330 | PHASE3 | COMPLETED | Vaginal Infection Study |
| NCT01420510 | PHASE2/PHASE3 | UNKNOWN | Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis |
| NCT01867164 | PHASE3 | COMPLETED | A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis |
| NCT02365389 | PHASE2/PHASE3 | COMPLETED | Once Daily In-situ Forming Versus Twice-daily Conventional Metronidazole Vaginal Gels for Treatment of Bacterial Vaginosis |
| NCT02515656 | PHASE3 | COMPLETED | Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis |
| NCT06771063 | PHASE2 | RECRUITING | A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients |
| NCT01122342 | PHASE1/PHASE2 | SUSPENDED | Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer. |
| NCT01593124 | PHASE2 | COMPLETED | Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation |
| NCT02316249 | PHASE2 | WITHDRAWN | Vaginal Creams to Reduce Vaginal Erosion in Pessary Users |
| NCT01436513 | PHASE1 | COMPLETED | A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions. |
| NCT05587283 | PHASE1 | UNKNOWN | Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women |
| NCT00503542 | EARLY_PHASE1 | COMPLETED | Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network |
| NCT06070454 | Not specified | RECRUITING | Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions |
| NCT07607470 | Not specified | NOT_YET_RECRUITING | Large Algorithm Setting and Validation Study |
| NCT00634608 | Not specified | COMPLETED | Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow |
| NCT00803127 | Not specified | COMPLETED | VS-Sense Result Reading Clarity |
| NCT01050465 | Not specified | COMPLETED | MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use |
| NCT02641717 | Not specified | COMPLETED | Validity of Patient-Collected Wet Mounts |
| NCT02763696 | Not specified | UNKNOWN | Establishment of a Sensitive System for Analysis of Child-bearing Women Vaginal Microbiota |
| NCT03151928 | Not specified | COMPLETED | Diagnostic Accuracy By Providers Study |
| NCT03585049 | Not specified | COMPLETED | Microscopic Images for the Development of a Rapid Vaginitis Diagnostic Device |
| NCT04676503 | Not specified | COMPLETED | Vaginal and Rectal Colonization of Lactobacillus Crispatus NTCVAG04 Following Oral Administration in Patients With History of Vaginitis/Vaginosis |
| NCT04816903 | Not specified | UNKNOWN | Gyni™ Study With Leumit Health Services |
| NCT04885556 | Not specified | UNKNOWN | Evaluation of a Novel Female Hygiene Device for Postcoital Discomfort |
| NCT04984460 | Not specified | UNKNOWN | Morphological Detection of Liquid-based Thin-layer Film-making Fungi for Fungal Vaginitis in Multiple Hospitals |
| NCT05396261 | Not specified | COMPLETED | a Flexible Wound Dressing for the Management of Genital Skin Conditions |
| NCT05557318 | Not specified | UNKNOWN | Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge |
| NCT05652959 | Not specified | COMPLETED | Real-world Performance and Safety of Cerviron® in the Treatment of Vaginitis |
| NCT05670535 | Not specified | COMPLETED | Sjögren and Gynecologic Considerations |
| NCT05882851 | Not specified | COMPLETED | Effect of Nutrition in the Treatment of Vaginitis |
| NCT06165354 | Not specified | COMPLETED | Effects of LiveSpo X-SECRET in SupportiveTreatment of Vaginitis |
| NCT06438575 | Not specified | COMPLETED | Point of Care Diagnosis of Vaginal Infections |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ESTRADIOL | 4 | 2 |
| BUTOCONAZOLE NITRATE | 4 | 1 |
| CLINDAMYCIN | 4 | 1 |
| CLINDAMYCIN PHOSPHATE | 4 | 1 |
| CLOTRIMAZOLE | 4 | 1 |
| FLUCONAZOLE | 4 | 1 |
| IMIQUIMOD | 4 | 1 |
| NONOXYNOL 9 | 4 | 1 |
| NYSTATIN | 4 | 1 |
| TESTOSTERONE PROPIONATE | 4 | 1 |
| TINIDAZOLE | 4 | 1 |
| TROLAMINE | 2 | 1 |
| CHEMBL450895 | 0 | 1 |
| CHEMBL4791312 | 0 | 1 |
| CHEMBL297687 | 0 | 1 |
| CHEMBL3792763 | 0 | 1 |
| YEAST, DRIED | -1 | 1 |